1. Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell. 2020;181:865–e12.
2. Amitai G, Sorek R. CRISPR-Cas adaptation: Insights into the mechanism of action. Nat Rev Microbiol. 2016;14:67–76.
3. Arslan Z, Hermanns V, Wurm R, Wagner R, Pul Ü. Detection and characterization of spacer integration intermediates in type I-E CRISPR-Cas system. Nucleic Acids Res. 2014;42:7884–93.
4. Athukoralage JS, McMahon SA, Zhang C, Grüschow S, Graham S, Krupovic M, et al. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity. Nature. 2020;577:572–5.
5. Babu M, Beloglazova N, Flick R, Graham C, Skarina T, Nocek B, et al. A dual function of the CRISPR-Cas system in bacterial antivirus immunity and DNA repair. Mol Microbiol. 2011;79:484–502.